Alan C. Moses

6.8k citations

82 papers · 5.5k indexed · 2 hit papers · h-index 40

Impact in

Endocrinology, Diabetes and Metabolism top 0.2%
- Growth Hormone and Insulin-like Growth Factors
- Diabetes Treatment and Management
- Diabetes Management and Research
- Thyroid Disorders and Treatments
Endocrine and Autonomic Systems top 5%

Papers in

Endocrinology, Diabetes and Metabolism 62
- Growth Hormone and Insulin-like Growth Factors 35
- Diabetes Management and Research 19
- Diabetes Treatment and Management 18
- Thyroid Disorders and Treatments 9
- Hyperglycemia and glycemic control in critically ill and hospitalized patients 6
Molecular Biology 34
- Metabolism, Diabetes, and Cancer 25
- Muscle Physiology and Disorders 4

Co-authors: S. Peter Nissley Matthew M. Rechler Jeffrey S. Flier Donatella Tramontano Sidney H. Ingbar Bernard Zinman John B. Buse David R. Clemmons
Journals: Endocrinology (16 papers)The Journal of Clinical Endocrinology & Metabolism (12 papers)Diabetes (5 papers)Diabetes Obesity and Metabolism (4 papers)European Journal of Biochemistry (3 papers)
Partner nations: United States Denmark Canada

In The Last Decade

Alan C. Moses

81 papers receiving 5.3k citations

Hit Papers

align trajectories log scale

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes 2017 · 409 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 New England Journal of Medicine
2010 Endocrinology

Peers

Countries citing papers authored by Alan C. Moses

Since Specialization

Citations

This map shows the geographic impact of Alan C. Moses's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan C. Moses with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan C. Moses more than expected).

Fields of papers citing papers by Alan C. Moses

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan C. Moses. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan C. Moses. The network helps show where Alan C. Moses may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alan C. Moses, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alan C. Moses Line = papers co-authored together Alan C. Moses links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) Therapeutic Innovation & Regulatory Science ·(unknown), María Giulianna Cano Silva, Ryousuke Ito, Ida Carøe Helmark, Lars Endahl, Z. Y. Wang, Anders Hvelplund, T. Gibian, Alan C. Moses	2018	1
2	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus JACC Heart Failure ·Abhinav Sharma, Lauren B. Cooper, Mona Fiuzat, Robert J. Mentz, João Pedro Ferreira, Javed Butler, David Fitchett, Alan C. Moses, Christopher O’Connor, Faı̈ez Zannad	2018	19
3	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes New England Journal of Medicine ·Steven P. Marso, Darren K. McGuire, Bernard Zinman, Neil R Poulter, Scott S. Emerson, Thomas R. Pieber, Richard E. Pratley, 黎波, Martin Lange, Kirstine Brown‐Frandsen, Alan C. Moses, Simon Skibsted, Kajsa Kvist, John B. Buse Hit paper breakdown →	2017	409
4	LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes Pancreas ·William M. Steinberg, Michael A. Nauck, Bernard Zinman, Gilbert H. Daniels, Richard M. Bergenstal, Johannes F.E. Mann, Lasse Steen Ravn, Alan C. Moses, Mette Stockner, Florian M.M. Baeres, Steven P. Marso, John B. Buse	2014	56
5	Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials The Lancet Diabetes & Endocrinology ·Bernard Zinman, J. Hans DeVries, Bruce W. Bode, David Russell‐Jones, Lawrence A. Leiter, Alan C. Moses, Thue Johansen, Robert E. Ratner	2013	34
6	Diabetes Prevention American Journal of Preventive Medicine ·Alan C. Moses, Katja Krebs, Anne Phillips	2013	5
7	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial American Heart Journal ·Steven P. Marso, Neil R Poulter, Steven E. Nissen, Michael A. Nauck, Bernard Zinman, Gilbert H. Daniels, Stuart Pocock, William M. Steinberg, Richard M. Bergenstal, Johannes F.E. Mann, Lasse Steen Ravn, Kirstine Brown Frandsen, Alan C. Moses, John B. Buse	2013	175
8	Empowering People with Diabetes: Improving Perceptions and Outcomes with Technical Advances in Insulin Pens Postgraduate Medicine ·David S. Oyer, I Gusti Ngurah Agung Gde Sastra Bahu, Alan C. Moses	2012	4
9	GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide The Journal of Clinical Endocrinology & Metabolism ·László Hegedüs, Alan C. Moses, Milan Zdravković, Fengyuan Wan, Gilbert H. Daniels	2011	158
10	Short-Term Hyperthyroidism Has No Effect on Leptin Levels in Man¹ The Journal of Clinical Endocrinology & Metabolism ·Christos S. Mantzoros, Harold N. Rosen, Susan L. Greenspan, Jeffrey S. Flier, Alan C. Moses	1997	76
11	Isolated combined growth hormone and gonadotrophin deficiency due to hypothalamic dysfunction, associated with insulin resistance Clinical Endocrinology ·O C Manintveld, Alan C. Moses	1995	1
12	Somatostatin Inhibits Deoxyribonucleic Acid Synthesis Induced by Both Thyrotropin and Insulin-Like Growth Factor-I in FRTL5 Cells* Endocrinology ·N. Suwan, Alan C. Moses	1990	52
13	Adenosine Has Divergent Effects on Deoxyribonucleic Acid Synthesis in FRTL5 Cells: Inhibition of Thyrotropin-Stimulated and Potentiation of Insulin-Like Growth Factor-I-Stimulated Thymidine Incorporation* Endocrinology ·Alan C. Moses, Donatella Tramontano, Bianca Maria Veneziani, Albert G. Frauman	1989	17
14	The A1 adenosine receptor antagonist 1,3, dipropyl-8-cyclopentylxanthine (DPCPX) displays adenosine agonist properties in the FRTL5 thyroid cell line Biochemical and Biophysical Research Communications ·Albert G. Frauman, Alan C. Moses	1989	10
15	Differentiation-Dependent Phosphorylation of a 175,000 Molecular Weight Protein in Response to Insulin and Insulin-Like Growth Factor-I in L6 Skeletal Muscle Cells* Endocrinology ·Francesco Bèguinot, C. Ronald Kahn, Alan C. Moses, Morris F. White, Robert J. Smith	1989	19
16	Production of insulin-like growth factor binding protein(s) (IGF-BPs) by human placenta: Variation with gestational age Placenta ·Michael E. Fant, Hamish N. Munro, Alan C. Moses	1988	8
17	Phosphorylation of insulin-like growth factor I receptor by the insulin receptor tyrosine kinase in intact cultured skeletal muscle cells Biochemistry ·Francesco Bèguinot, Robert J. Smith, C. Ronald Kahn, Ruth Maron, Alan C. Moses, Morris F. White	1988	29
18	Evidence that Receptor Aggregation may Play a Role in Transmembrane Signaling through the Insulin-Like Growth Factor-I Receptor Molecular Endocrinology ·Nobuhiko Ikari, Hiroko Yoshino, Alan C. Moses, Jeffrey S. Flier	1988	20
19	Adenosine 3′,5′-Monophosphate Mediates Both the Mitogenic Effect of Thyrotropin and Its Ability to Amplify the Response to Insulin-Like Growth Factor I in FRTL5 Cells* Endocrinology ·Donatella Tramontano, Alan C. Moses, Bianca Maria Veneziani, Sidney H. Ingbar	1988	128
20	The Role of Adenosine 3′,5′-Monophosphate in the Regulation of Receptors for Thyrotropin and Insulin-Like Growth Factor I in the FRTL5 Rat Thyroid Follicular Cell* Endocrinology ·Donatella Tramontano, Alan C. Moses, Sidney H. Ingbar	1988	37

About Alan C. Moses

Alan C. Moses is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology, Family Practice, Endocrine and Autonomic Systems and Obstetrics and Gynecology, having authored 82 papers that have together received 5.5k indexed citations. Recurring topics across this work include Growth Hormone and Insulin-like Growth Factors (35 papers), Metabolism, Diabetes, and Cancer (25 papers), Diabetes Management and Research (19 papers), Diabetes Treatment and Management (18 papers), Thyroid Disorders and Treatments (9 papers), Pancreatic function and diabetes (7 papers), Hyperglycemia and glycemic control in critically ill and hospitalized patients (6 papers) and Muscle Physiology and Disorders (4 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (3.7k citations), Endocrine and Autonomic Systems (246 citations), Molecular Biology (2.2k citations), Surgery (1.2k citations) and Pharmaceutical Science (155 citations). Alan C. Moses has collaborated with scholars based in United States, Denmark and Canada. Frequent co-authors include S. Peter Nissley, Matthew M. Rechler, Jeffrey S. Flier, Donatella Tramontano, Sidney H. Ingbar, Bernard Zinman, John B. Buse, David R. Clemmons, Gary W. Cushing and Steven P. Marso. Their work appears in journals such as Endocrinology, The Journal of Clinical Endocrinology & Metabolism, Diabetes, Diabetes Obesity and Metabolism and European Journal of Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact